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Several sensitive methods are available for red blood cell (RBC) antibody screening.
Among these, gel and glass card systems have demonstrated comparably good perfor-
mance in retrospective studies and are widely used in routine patient diagnostics, but their
performance in prospective studies has not been sufficiently characterised.
Patients and methods
Gel card (Bio-Rad DiaMed) and glass bead-based (Ortho Clinical Diagnostics) column
agglutination technologies were used to screen for antibodies prospectively (group A) and
for antibody identification in stored and fresh samples known to contain RBC antibodies ret-
rospectively (group B). Untreated reagent RBCs and either papain-treated (Bio-Rad) or
ficin-treated panel C cells (Ortho) were used for antibody identification.
Results
RBC-reactive antibodies were detected in 22 of 1000 group A samples, three of which
tested positive only by gel card agglutination, and four only by glass bead agglutination
(including one false positive each). Group B comprised 202 sera with known antibodies: 33
of these samples contained 36 antibodies detected only by gel card agglutination, whereas
9 samples contained antibodies detectable only by glass bead-based agglutination. Dis-
crepancies mostly involved weak antibodies reactive by enzyme only. Two sera contained
antibody mixtures that neither system detected completely. Of note, in antibody differentia-
tion batches one and two, anti-Lua was reactive in 7 of 7 and 1 of 8 samples, respectively.
Conclusion
Both column agglutination tests for red cell antibodies had equal sensitivity and specificity
with unstored samples. In stored samples, weak and enzyme-only antibodies were more fre-
quently detected with the gel card system.
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Introduction
Red blood cell (RBC) immunization is one of the most frequent side effects of blood transfu-
sion. Up to 8% of RBC recipients may develop new antibodies after a single transfusion epi-
sode [1]. Patients that develop alloantibodies are also at risk to develop autoimmunization
against RBC antigens. In fact, alloimmunization is the most frequent cause for autoimmuniza-
tion [2]. As about half to two third of the alloantibodies become undetectable within four to
five years [3–5], the affected patients are at risk of developing delayed serologic or hemolytic
transfusion reactions after subsequent blood transfusions. Therefore, RBC antibodies are
among the most common causes of transfusion morbidity [6, 7]. RBC antibodies were also the
most frequent transfusion cause of death accounting for 10 out of 25 cases in a recent report of
the European Commission [8]. Sensitive detection of these antibodies is essential.
Several techniques have been developed for this purpose. Low Ionic Strength Solution
(LISS)-Antihuman Globulin, polyethylene glycol and polybrene have been introduced as reac-
tion enhancers, and antigen-antibody reactions were transferred from tube to column aggluti-
nation or microplate solid-phase reactions. Among these, antihuman globulin non-tube tests
have been found to be superior to the others [9]. Solid-phase reactions on microtiter plates
[10] are known to be sensitive but lack sufficient specificity: They produce inconclusive results
2.5 to 10 times more frequently than column systems [11, 12]. Column agglutination may be
performed using cards that either trap agglutinates in a dextran-acrylamide matrix, or in a
matrix consisting of glass beads [13–15]. These similar methods have been investigated with
stored samples, blood donors or in house reagent cells. Data on the performance in patient
diagnostics is incomplete.
Therefore, we compared gel with glass bead based column agglutination technologies. Our
results indicate that both systems have equal sensitivity and specificity in screening. However,
we observed differences in identification related to the setup of the panels.
Material and methods
Reagents
RBC antibody screening and identification tests from Bio-Rad DiaMed (Cressier-sur-Morat,
Switzerland; gel card) [13] and Ortho Clinical Diagnostics (Raritan, New Jersey, USA; glass
card) [14] were used according to the manufacturer’s instructions. Reaction strength was
graded on a scale of zero (negative) to four-plus (complete agglutination). Screening was per-
formed using a panel of three reagent cells in antihuman globulin without enzyme-treated
cells (ID-DIA Panel I-II-III test cells, Surgiscreen test cells), which homozygously expressed
the antigens D, c, Fya, Fyb, Jka, Jkb, S, and s as well as C, E, e, CW, K, k, Kpa, Kpb, Lea, Leb, M,
N, Lua, Lub, and P1. Antibody identification with both systems was performed using untreated
and either papain-treated (DiaMed) or ficin-treated (Ortho) reagent cells (ID-Dia Panel or
Resolve Panel C). Untreated reagent cells were tested in antihuman globulin (LISS/Coombs
gel cards, BioVue System Poly Cassettes), and enzyme-treated cells in a saline milieu (neutral
gel card, BioVue neutral cassettes). Gel card samples were pipetted manually, and glass card
samples were pipetted using an automated platform (AutoVue Innova). Reactions were classi-
fied as specifically positive if at least homozygous cells were weakly reactive (+/–).
Patients and samples
Two groups of samples were investigated as approved by the local ethics committee (Indepen-
dent Ethics Committee at the University of Regensburg, 17-537-101). Group A consisted of
1000 unstored local routine EDTA-anticoagulated samples that were recruited from local
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patients of the University Hospital Regensburg with a case mix index of 2.0 and 835 beds that
are mainly focused on intensive care with approximately 28,000 antibody screens and 18,000
red cell transfusions annually. These were screened for antibodies prospectively and in parallel
(by both test systems) from the end of March to the end of April 2017. If a sample tested posi-
tive by one or both methods, antibody identification was performed by both systems.
Group B consisted of 202 sera with known antibodies that were mainly collected locally as
well as from cooperating blood banks. Antibody identification of these samples was performed
retrospectively and in parallel from the end of March to the middle of August 2017. RBC
screening was not performed in group B.
Results
Prospective antibody screening was performed in a total of 1000 samples in group A (Table 1)
using both gel cards and glass bead cards. Irregular antibodies were detected in a total of 22
samples (2.2%) from 17 group A patients (2.5%), seven samples of which had more than one
antibody (32%).
Both test systems yielded true positive results for 17 samples containing mostly clinically
relevant antibodies (Table 2). A further 3 samples only tested positive by gel card (including
one false positive), whereas additional 4 samples were only positive by glass card (also includ-
ing one false positive, Table 3 and Table 4). Samples were regarded as false positive if positive
screening could not be confirmed by differentiation (ie. sporadic reaction without determin-
able antigen specificity). Altogether, reaction discrepancies were observed in 7 of 24 samples
(29%), all of which had weak reactions graded one-plus or lower (Table 4). This included one
sample with a true positive glass card reaction and a false negative gel card reaction: antibody
differentiation was possible in the case of the gel card system but not the glass card system. In
Table 1. Patient and sample characteristics.
Group A Group B
Patients (n) 687 180
Patient age� (years) 60 (range: 1–94) 68 (range: 11–92)
Samples (n) 1000 202
�Data expressed as median with range in parenthesis
https://doi.org/10.1371/journal.pone.0210099.t001
Table 2. Concordant positive RBC antibody test results.
Group Identification results Total no. of samples and relevance
A D, C, E, WAA 1, relevant
A Fya 2, relevant
A D 2, relevant
A Lua 3, relevant
A Cw 1, relevant
A C, D 3, relevant
A M 1, relevant
A D, E 1, relevant
A D, Jka 1, relevant
A Daratumumab 2, irrelevant
WAA, warm-reactive autoantibodies
https://doi.org/10.1371/journal.pone.0210099.t002
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group A, the difference between the two systems was not significant (in McNemar’s test, the p-
value was 1).
Group B samples consisted of 202 known positive samples from 180 patients with a total of
327 antibodies. 82 (41%) of these samples contained more than one antibody (including auto-
antibodies). As group B included only those sera that were reactive upon retesting, sensitivity,
specificity, and accuracy could not be determined for that group. In fact, a further 10 samples
were non-reactive after storage at –30˚C for up to 5 years and therefore not included.
Both systems were positive for 158 of the 202 antibody-containing group B samples, includ-
ing two samples with incomplete test results with both systems (Table 4). Altogether, gel card
testing produced false negative results for 11 samples, and glass card testing yielded false nega-
tive results for 35 samples.
There were discrepancies between results for certain blood groups. In group B samples,
antibodies to Rh antigens appeared to be more reactive in the gel card system. Of the 53 group
B sera containing anti-C, 40 were reactive in glass card testing compared to 52 in gel card test-
ing. Of a total of 123 samples containing antibodies against Rh antigens, 106 were detected by
the glass card system compared to 122 by the gel card system. Warm-reactive autoantibodies
(WAA), which usually display some Rh reactivity, were detected in 18 of 24 samples (glass
card) versus 22 of 24 samples (gel card). This difference indicates that reagent cells were more
intensely treated by the gel card system’s enzyme (papain) than by that of the glass card system
(ficin) and, thus, were more reactive to antibodies to the Rh system.
Autoantibodies were present in 26 samples: 18 were detected by both systems; six by gel
card only; and two by glass card only. This finding is consistent with the more intense enzyme
treatment of reagent cells associated with the gel card system.
No difference between systems was observed for antibodies to Jk antigens. A total of 13
group B sera contained anti-Jka: nine were detected by both systems, two by gel card testing
only, and another two by glass card testing only.
Antibodies to the Kell system were present in 22 group B samples: The glass card system
detected all twenty-two while the gel card system detected twenty.
In group B, 44 of 202 samples (22%) gave discrepant results using the two assays (Table 4)
and this difference was significant (p< 0.005 in McNemar’s test). This included seven samples
containing anti-Lua, which was not detected or was incompletely recognized in glass card
Table 3. RBC antibody test results in Group A (prospective screening samples) versus Group B (stored samples).
Group A Group B
Gel card Glass card Gel card Glass card
Samples with correct positive test 19 20 191 167
Samples with incorrect positive test 1 1 0 0
Samples with correct negative test 977 977 0 0
Samples with incorrect negative or incomplete test 3 2 11 35
Accuracy 99.6% 99.7% NaN NaN
Sensitivity 86.36% 90.90% NaN NaN
Specificity 99.90% 99.90% NaN NaN
PPV 95.00% 95.24% 94.55% 82.67%
NPV 99.69% 99.80% NaN NaN
Accuracy calculated as (true positives + true negatives) / all samples; NaN, not a number; NPV, negative predictive value calculated as true negatives / (true negatives
+ false negatives); PPV, positive predictive value calculated as true positives / (true positives + false positives); sensitivity calculated as true positives / (true positives
+ false negatives); specificity calculated as true negatives / (true negatives + false positives)
https://doi.org/10.1371/journal.pone.0210099.t003
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testing. All of these failed in the latter of two reagent cell batches, in which only one additional
anti-Lua was recognized. The newer identification batch was Lua-positive for one of eleven
cells. In contrast, the previous batch (which was also used for group A identification) recog-
nized all of seven previously tested group B samples that contained anti-Lua. This previous
batch was Lua-positive for two of eleven cells.
Discussion
Antibodies to RBC were observed in 2.2% of Group A samples. Two samples were positive
because of daratumumab, the immunization frequency was therefore 2.0% after exclusion of
these samples. This is comparable to frequencies found in other studies, e.g. in 0.9% of healthy
blood donors [16], and in 2.2% [17] or 2.9% [16] of patients, respectively. Immunization
depends largely on whether the subject has received previous transfusions [1]. It can be
Table 4. Discordant RBC antibody test investigation results.
Type of discrepancy Group Gel card Glass card Total no. of samples and relevance
of discrepancyscreening identification screening identification
Glass card positive, gel card initially
negative or incomplete
A Negative Negative Positive Lua 1, relevant
A Negative K Positive Negative 1, relevant
A Negative WAA Positive WAA 1, irrelevant
A Negative Negative Positive No antibody
specificity�
1, irrelevant
B Negative K (n = 2); Jka; Lua; 4, relevant
B Negative N; P1 2, irrelevant
B E E + C 1, relevant
B Cw Cw + Jka 1, relevant
B Jka Jka + WAA 1, irrelevant
Gel card positive, glass card initially
negative or incomplete
A Positive D + E Negative D + E 1, relevant
A Positive WAA Negative WAA 1, irrelevant
A Positive Negative Negative Negative 1, irrelevant
B M No antibody
specificity �
1, relevant
B Leb No antibody
specificity �
1, irrelevant
B M; Jka; Lea; C; Lua (n = 4); E
+ M; Jka + Lua
Negative 10, relevant
B D + C D 6, relevant
B C + WAA C 1, irrelevant
B E + WAA E 1, irrelevant
B D + C + WAA D + C 2, irrelevant
B D + C + E D + E 4, relevant
B D + E D (n = 2); E 3, relevant
B D + C + E + WAA D + E 1, relevant
B D + C + E + WAA D + C + E 1, irrelevant
B D + C +Jka + WAA D + Jka + WAA 1, relevant
B D + C + Lua D + C 1, relevant
Both incomplete B E Lua 1, relevant
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regarded as a common phenomenon, occurring in 1% to 10% of adult transfusion recipients
[18, 19].
In this comparative study of two commercially available red blood cell antibody screen-
ing systems, the glass card method was found to be comparable to the gel card system in
prospective antibody screening (group A, sensitivities of 90.9% vs. 86.4%, respectively. This
confirms roughly the results of a recent Spanish study, which found sensitivities of 87.5% to
100% with samples that were stored up to 72 h at 2–8˚C. The reported numbers in that
study were higher after the authors included a different group of known positive samples
[20]. The primary screening samples group had a low rate of non-negative tests of 0.9%,
because 80% of the samples were from healthy blood donors. This impairs the applicability
of the results to patient diagnostics, as not only less, but also different antibodies occur in
healthy donors.
In a recent prospective study in Thailand, sensitivities of 100% and 85.7% were found for
the glass card and gel card system, respectively, for antibodies regarded as significant [21]. Sen-
sitivities for clinically insignificant antibodies were lower: only 53.6% for the glass card and
28.5%–35.7% for two different gel card systems, respectively. However, the Thai researchers
also regarded antibodies to Mia, Lea, and M, which may cause hemolysis in some cases, as
insignificant. These antibodies were found in tube testing, which is otherwise known to be sig-
nificantly less sensitive [11, 22]. These authors used reagent cells from the Thai Red Cross Soci-
ety for all methods. If the same low ionic strength buffer was used for all methods, this could
have impaired methods that depend on the buffer’s composition [23].
Weisbach et al. [11] found that the glass card and gel card systems have sensitivities of
90.5% and 93.5%, respectively, but they used stored samples for their analysis (comparable to
our group B). In our group B, the gel card system was superior to the glass card system for ana-
lyzing stored samples with known antibodies. Accordingly, we calculated the positive predic-
tive value (PPV) of the gel card and glass card system to be 95% and 82%, respectively. This
difference is plausible as testing included antibodies that were only reactive with enzyme-
treated cells and enzyme-treatment is more intense for gel card testing. However, the clinical
significance of enzyme-only antibodies is unclear. Antibody screening is generally performed
without enzyme-treated cells because the delay required to obtain additional information (e.g.,
on weak warm-reactive autoantibodies, which are clinically irrelevant) results in a disadvan-
tage that exceeds the potential benefit [24]. In addition, the potential harm of enzyme-only
antibodies has long been a matter of debate [25, 26].
Solid-phase testing is established without enzyme-treated cells and has been found to
achieve superior sensitivities [11, 27]. This includes testing for prenatal anti-D, which could be
detected up to the fifth dilution step in solid-phase testing, while card testing was generally
only positive up to the fourth dilution step [28]. The solid-phase system’s superior sensitivity
contrasts with its low specificity [12]. Weisbach et al. found inconclusive reactivities, possibly
mostly false positive reactions, in 1.38% and 0.13% of samples tested with a solid-phase and gel
card system, respectively [11]. Inconsistent results were also found by Quillen et al., who
reported for automated solid-phase systems non-repeatability for the detection of antibodies
to E, Jka, and Fya [29]. A recent comparison found unspecified reactions in 7 cases for the solid
phase assay compared to 2 for gel card agglutination [12].
In general, studies without sample storage that reflect real world testing were based on a
small number of positive samples, which is of questionable significance. The use of stored sam-
ples, in contrast, allows investigators to analyze a larger number of samples. Antibodies are
usually considered robust to pre-analytical variation. If, for instance, antibodies to Toxoplasma
are stored at –20˚C, there occurs an approximately 8% decrease in IgG antibodies and a 13%
decrease in IgM antibodies, both of which are less than analytical variation [30]. However,
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compared to antibodies to red cell antigens, antibodies to various viral antigens are more stable
in vivo, with half-lives ranging from 50 to 200 years [31]. In contrast, antibodies to red cells
have much shorter half-lives of less than 4 years overall [3, 4], and the half-live is dependent
from the specificity [3–5]. There are no robust data on red cell antibody decay during storage,
but it is likely that storage also affects antibodies differently. As all methods have antibodies
that react especially well with the respective method, this bearing damage would effect the per-
formance with stored samples. This effect was apparent with our data. It limits the interpreta-
tion of results and the use of statistical data from stored samples.
Batch-to-batch variation of reagent cells was detected as an incidental finding of our study.
These fluctuations impacted the test sensitivity for Lua, a less frequent antigen. The corre-
sponding antibody was weakly reactive in many of the stored samples and was only visible in
some of the Lua-positive cells. Batch-to-batch variation of reagent cells is possible, as reagent
cell donors have different antigen expression levels. Cell storage and preparation methods may
also impact reactivity. Therefore, decreased sensitivity with differentiation panels that contain
only one instead of two antigen-positive cells is plausible. One group recently published similar
findings for Kpa, which increases the sensitivity of the test system if included in screening at
the cost of having four instead of three cells per sample in the screening [12].
In conclusion, RBC antibody screening sensitivity is important to detect antibodies in eva-
nescence. This favors the use of enzyme-treated cells and to include all important antigens, if
blood provision was thereby not impaired.
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